Feb 24, 2026
# SYNTHESIS BRIEF: Precision & Preventive Health Systems
## Current State Summary
Precision and preventive health systems represent a well-documented but chronically underfunded paradigm shift in healthcare delivery. The evidence base is robust: prevention ROI ranges from 2.65:1 to 14:1 depending on intervention type, and 70-90% of major chronic disease burden is theoretically preventable through modifiable risk factors. Proof-of-concept programs like Geisinger's Fresh Food Farmacy demonstrate dramatic outcomes (2.1-point HbA1c reductions, 80% cost reduction) at modest per-patient costs (~$2,400/year). However, despite this evidence, only 3% of U.S. healthcare spending goes to prevention, revealing a fundamental implementation gap driven by misaligned incentives, fragmented data systems, and fee-for-service payment models that reward treatment over prevention.
---
## 5 Most Important Validated Facts
1. **Prevention ROI is consistently positive but variable:** CDC data confirms 14:1 returns for community-based prevention over 5 years; diabetes-specific programs show more modest but still positive 2.65:1 returns. *Evidence strength: Strong for program-level; weaker for population-scale extrapolation.*
2. **Preventable burden dominates chronic disease:** 80% of CVD, 90% of T2 diabetes, and 30% of cancers are attributable to modifiable risk factors (WHO). This ceiling defines the theoretical opportunity.
3. **Polygenic risk scores remain limited:** PRS currently explain only 5-10% of disease variance—useful for risk stratification at population level but insufficient for individual clinical decisions.
4. **Integrated delivery models work at pilot scale:** Geisinger's program demonstrates that combining social determinants (food access) with clinical care and EHR-integrated screening produces outsized returns (~$24,000 saved per patient annually vs. $2,400 cost).
5. **Industrial predictive maintenance offers a solved analog:** GE Aviation achieved 70% reduction in unplanned maintenance through sensor-based prediction—demonstrating that the technical and organizational challenges of "predict-and-prevent" are solvable when incentives align.
---
## Top Uncertainties & Resolving Data
| Uncertainty | What Would Resolve It |
|-------------|----------------------|
| **Does prevention ROI hold at population scale?** | Multi-site RCTs with 5+ year follow-up across diverse payer/provider systems |
| **Which populations benefit most from PRS-guided intervention?** | Stratified outcome studies comparing PRS-directed vs. standard prevention protocols |
| **Can incentive realignment sustain prevention investment?** | Longitudinal analysis of value-based care contracts that explicitly fund prevention |
| **What's the minimum viable technology stack?** | Comparative effectiveness studies of high-tech (continuous monitoring) vs. low-tech (community health workers) approaches |
---
## Consensus Strategy vs. Competing Strategy
**Consensus Strategy:** Integrate precision risk stratification (genomic + social determinants) with proven lifestyle interventions, delivered through value-based payment models that allow payers to capture long-term savings. Scale programs like Fresh Food Farmacy that address root causes while using EHR integration for targeting.
**Competing Strategy:** Skip precision targeting entirely—universal prevention programs (e.g., sugar taxes, walkable cities, food policy) may deliver greater population impact at lower per-capita cost than individualized interventions, without requiring the data infrastructure or genomic advances that remain immature.
*The tension is real:* Precision approaches risk becoming "prevention for the privileged" while structural interventions face political barriers but offer broader reach.
---
## Key Milestones
### 6 Months
- Publish standardized ROI methodology for prevention programs (current estimates vary 5x)
- Launch at least 2 multi-payer pilots testing shared savings for prevention investments
### 12 Months
- Validate PRS-guided intervention protocols in ≥3 health systems with diverse populations
- Establish data-sharing frameworks enabling social determinants integration with clinical EHRs
### 24 Months
- Demonstrate sustained (3+ year) cost reduction in scaled prevention programs (n>50,000)
- Achieve CMS reimbursement pathway for at least one integrated prevention model (food-as-medicine or equivalent)
---
## What's Missing
The research does not address: (1) **workforce requirements**—who delivers prevention at scale and how they're trained/paid; (2) **patient engagement sustainability**—dropout rates and long-term adherence outside controlled programs; (3) **equity implications**—whether precision approaches widen or narrow health disparities.
---
## Implication for Action
**For funders:** Prioritize investments in incentive-alignment mechanisms (value-based contracts, shared savings models) over additional technology development—the bottleneck is payment structure, not science. **For practitioners:** Adopt hybrid models that combine low-cost social determinant interventions (proven) with selective precision targeting (promising but unvalidated at scale), and rigorously measure 3-year outcomes to build the evidence base that's still missing.
## Current State Summary
Precision and preventive health systems represent a well-documented but chronically underfunded paradigm shift in healthcare delivery. The evidence base is robust: prevention ROI ranges from 2.65:1 to 14:1 depending on intervention type, and 70-90% of major chronic disease burden is theoretically preventable through modifiable risk factors. Proof-of-concept programs like Geisinger's Fresh Food Farmacy demonstrate dramatic outcomes (2.1-point HbA1c reductions, 80% cost reduction) at modest per-patient costs (~$2,400/year). However, despite this evidence, only 3% of U.S. healthcare spending goes to prevention, revealing a fundamental implementation gap driven by misaligned incentives, fragmented data systems, and fee-for-service payment models that reward treatment over prevention.
---
## 5 Most Important Validated Facts
1. **Prevention ROI is consistently positive but variable:** CDC data confirms 14:1 returns for community-based prevention over 5 years; diabetes-specific programs show more modest but still positive 2.65:1 returns. *Evidence strength: Strong for program-level; weaker for population-scale extrapolation.*
2. **Preventable burden dominates chronic disease:** 80% of CVD, 90% of T2 diabetes, and 30% of cancers are attributable to modifiable risk factors (WHO). This ceiling defines the theoretical opportunity.
3. **Polygenic risk scores remain limited:** PRS currently explain only 5-10% of disease variance—useful for risk stratification at population level but insufficient for individual clinical decisions.
4. **Integrated delivery models work at pilot scale:** Geisinger's program demonstrates that combining social determinants (food access) with clinical care and EHR-integrated screening produces outsized returns (~$24,000 saved per patient annually vs. $2,400 cost).
5. **Industrial predictive maintenance offers a solved analog:** GE Aviation achieved 70% reduction in unplanned maintenance through sensor-based prediction—demonstrating that the technical and organizational challenges of "predict-and-prevent" are solvable when incentives align.
---
## Top Uncertainties & Resolving Data
| Uncertainty | What Would Resolve It |
|-------------|----------------------|
| **Does prevention ROI hold at population scale?** | Multi-site RCTs with 5+ year follow-up across diverse payer/provider systems |
| **Which populations benefit most from PRS-guided intervention?** | Stratified outcome studies comparing PRS-directed vs. standard prevention protocols |
| **Can incentive realignment sustain prevention investment?** | Longitudinal analysis of value-based care contracts that explicitly fund prevention |
| **What's the minimum viable technology stack?** | Comparative effectiveness studies of high-tech (continuous monitoring) vs. low-tech (community health workers) approaches |
---
## Consensus Strategy vs. Competing Strategy
**Consensus Strategy:** Integrate precision risk stratification (genomic + social determinants) with proven lifestyle interventions, delivered through value-based payment models that allow payers to capture long-term savings. Scale programs like Fresh Food Farmacy that address root causes while using EHR integration for targeting.
**Competing Strategy:** Skip precision targeting entirely—universal prevention programs (e.g., sugar taxes, walkable cities, food policy) may deliver greater population impact at lower per-capita cost than individualized interventions, without requiring the data infrastructure or genomic advances that remain immature.
*The tension is real:* Precision approaches risk becoming "prevention for the privileged" while structural interventions face political barriers but offer broader reach.
---
## Key Milestones
### 6 Months
- Publish standardized ROI methodology for prevention programs (current estimates vary 5x)
- Launch at least 2 multi-payer pilots testing shared savings for prevention investments
### 12 Months
- Validate PRS-guided intervention protocols in ≥3 health systems with diverse populations
- Establish data-sharing frameworks enabling social determinants integration with clinical EHRs
### 24 Months
- Demonstrate sustained (3+ year) cost reduction in scaled prevention programs (n>50,000)
- Achieve CMS reimbursement pathway for at least one integrated prevention model (food-as-medicine or equivalent)
---
## What's Missing
The research does not address: (1) **workforce requirements**—who delivers prevention at scale and how they're trained/paid; (2) **patient engagement sustainability**—dropout rates and long-term adherence outside controlled programs; (3) **equity implications**—whether precision approaches widen or narrow health disparities.
---
## Implication for Action
**For funders:** Prioritize investments in incentive-alignment mechanisms (value-based contracts, shared savings models) over additional technology development—the bottleneck is payment structure, not science. **For practitioners:** Adopt hybrid models that combine low-cost social determinant interventions (proven) with selective precision targeting (promising but unvalidated at scale), and rigorously measure 3-year outcomes to build the evidence base that's still missing.